19.84SEK+2.69%Mkt Cap: 106.27M $P/E: —Today
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial fo…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap106.27M $
Enterprise Value97.30M $
Revenue (TTM)—
Gross Profit0 $
Net Income (TTM)-10.60M $
Revenue/Share—
Last Price19.84 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees8
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0008241491
Valuation
P/E (Trailing)—
P/E (Forward)-10.97
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B5.64
EPS (TTM)-49.66
EPS (Forward)-1.78
52W Range
7.05070% of range25.30
52W High25.30 SEK
52W Low7.050 SEK
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-65.08%
ROA-50.26%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.31M $
CapEx (TTM)—
FCF Margin—
FCF Yield-5.96%
Net Debt-6.19M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.01
Current Ratio5.74
Quick Ratio5.61
Book Value/Sh3.460 SEK
Cash/Share1.175 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating0.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)35.00 SEK
Upside (mean)+76.4%
Target Range30.00 SEK – 40.00 SEK
SEK30.00+76.4% to meanSEK40.00
# Analysts2
Ownership
Shares Out.56.00M
Float31.77M
Insiders29.87%
Institutions19.74%
Technical
SMA 5017.90 (+10.8%)
SMA 20018.75 (+5.8%)
Beta0.75
S&P 52W Chg18.16%
Avg Vol (30d)175.29K
Avg Vol (10d)145.85K
Technical Indicators
RSI (14)52.0
MACD0.5233
MACD Signal0.4361
MACD Hist.+0.0872
BB Upper20.88 SEK
BB Middle18.89 SEK
BB Lower16.90 SEK
BB Width21.09%
ATR (14)1.268 SEK
Vol Ratio (20d)2.07x